Harbor Capital Advisors Inc. Raises Holdings in Certara, Inc. $CERT

Harbor Capital Advisors Inc. lifted its stake in Certara, Inc. (NASDAQ:CERT) by 41.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,670 shares of the company’s stock after buying an additional 8,376 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Certara were worth $335,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of CERT. Versant Capital Management Inc boosted its stake in shares of Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock worth $27,000 after buying an additional 1,866 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Certara during the first quarter worth approximately $31,000. AlphaQuest LLC purchased a new position in Certara during the first quarter worth approximately $39,000. Quarry LP purchased a new position in Certara during the first quarter worth approximately $98,000. Finally, Associated Banc Corp purchased a new position in Certara during the first quarter worth approximately $101,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Insider Buying and Selling at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the sale, the insider directly owned 73,979 shares of the company’s stock, valued at approximately $807,850.68. The trade was a 40.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 2.33% of the company’s stock.

Certara Price Performance

CERT stock opened at $11.48 on Friday. The business has a fifty day moving average of $10.75 and a two-hundred day moving average of $11.26. The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 0.27. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of 229.65 and a beta of 1.43. Certara, Inc. has a 52-week low of $8.64 and a 52-week high of $15.69.

Certara (NASDAQ:CERT) last posted its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $104.57 million for the quarter, compared to analyst estimates of $104.14 million. Certara had a return on equity of 5.11% and a net margin of 1.97%.Certara’s revenue was up 12.1% compared to the same quarter last year. During the same period last year, the business earned $0.07 EPS. As a group, research analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on CERT shares. KeyCorp lowered their price target on Certara from $18.00 to $15.00 and set an “overweight” rating on the stock in a research report on Monday, July 14th. UBS Group lowered their price target on Certara from $17.50 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Morgan Stanley started coverage on Certara in a research report on Thursday, July 3rd. They set an “equal weight” rating and a $16.00 price target on the stock. Finally, Zacks Research upgraded Certara from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Five equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, Certara presently has a consensus rating of “Moderate Buy” and an average price target of $15.14.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.